Catastrophic Antiphospholipid Syndrome: Candidate Therapies for a Potentially Lethal Disease.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 28099080.
- Also identified by DOI 10.1146/annurev-med-042915-102529.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Catastrophic antiphospholipid syndrome (CAPS) is a potentially lethal disease that presents with rapidly progressive multiple organ thromboses. Anticoagulation, corticosteroids, intravenous immunoglobulin, and plasma exchange are the most commonly used treatments for CAPS patients. However, the high mortality despite these medications necessitates new treatment strategies. Following a brief review of current diagnostic and management strategies, we discuss the candidate therapies, i.e., hydroxychloroquine, rituximab, eculizumab, sirolimus, and defibrotide, that can be considered in CAPS patients refractory to traditional treatment.
Medical subject headings
- Antiphospholipid Syndrome